Top Markets
Coin of the day
Hubei Biocause Pharmaceutical Co., Ltd. Hubei Biocause Pharmaceutical Co., Ltd.

Hubei Biocause Pharmaceutical Co., Ltd.

000627
Rank in Stocks #9082
Hubei Biocause Pharmaceutical Co., Ltd., based in Jingmen, China, operates a... Hubei Biocause Pharmaceutical Co., Ltd., based in Jingmen, China, operates a multifaceted business. Its primary activities within China involve the provision of life and motor insurance policies. Additionally, the company is engaged in the pharmaceutical, chemical, and new energy fuel industries. Specifically, in the pharmaceutical field, it conducts contract research, development, and manufacturing of active pharmaceutical ingredients (APIs), intermediate compounds, and various drug forms such as tablets, granules, and capsules. Its chemical offerings include substances like dimethyl ether gas and a-chloropropionyl chloride. The firm also boasts an international presence, distributing its products to markets including the United States, the European Union, and other global locations.
Share Price
$0.2219522
Last synced: 2025-09-11
Market Cap
$1.10B
Change (1 day)
0.04%
Change (1 year)
0.17%
Country
CN
Trade Hubei Biocause Pharmaceutical Co., Ltd. (000627)
Revenue for Hubei Biocause Pharmaceutical Co., Ltd. (000627)
Revenue in Sep 2024 TTM: $11.64B
According to Hubei Biocause Pharmaceutical Co., Ltd. latest financial reports the company's current revenue (TTM) is $11.64B. In 2022 the company made a revenue of $7.19B a decrease compared to the revenue in the year 2021 that was $7.80B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Hubei Biocause Pharmaceutical Co., Ltd. from 2000 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $11.64B 65.85%
2023 $7.02B -2.39%
2022 $7.19B -7.80%
2021 $7.80B 16.95%
2020 $6.67B -7.46%
2019 $7.21B 60.19%
2018 $4.50B -45.18%
2017 $8.21B 235.32%
2016 $2.45B 2,837.70%
2015 $83.33M -36.00%
2014 $130.20M -18.41%
2013 $159.58M 27.62%
2012 $125.04M -30.47%
2011 $179.84M -5.88%
2010 $191.07M 35.24%
2009 $141.29M 6.03%
2008 $133.26M 16.42%
2007 $114.46M 59.34%
2006 $71.83M 11.78%
2005 $64.26M 14.85%
2004 $55.95M 9.55%
2003 $51.07M 21.26%
2002 $42.12M -2.10%
2001 $43.02M 10.51%
2000 $38.93M 0.00%
Revenue for similar companies or competitors